Table 2. Adjusted treatment effects on changes in hemoglobin 7, 14, and 28 days after an IPTi dose.

Adjusted between-group differences (g/dL) [95%CI]
	7 days after an IPTi dose			14 days after an IPTi dose			28 days after an IPTi dose
Treatment	Estimate	P-value a	Overall p-value b	Estimate	P-value a	Overall p-value b	Estimate	P-value a	Overall p-value b
Placebo	Ref		0.01	Ref		<0.001	Ref		0.07
SP	0.00 [-0.34 to 0.34]	1.0		0.06 [-0.22 to 0.34]	0.7		-0.07 [-0.28 to 0.13]	0.5
MQ	0.10 [-0.26 to 0.45]	0.6		-0.03 [-0.31 to 0.26]	0.8		0.08 [-0.13 to 0.29]	0.5
CD	-0.45 [-0.80 to -0.09]	0.01		-0.50 [-0.79 to -0.22]	0.001		-0.19 [-0.40 to 0.01]	0.07

Analyses adjusted for genotype, dose number, sex, site, weight (kg) and elevation (m).

^aP-values for adjusted treatment effects compared to chlorproguanil-dapsone (CD).

^bP-values for overall adjusted treatment effects. SP = sulfadoxine-pyrimethamine. MQ = mefloquine.